 |
|
|
 |
|
|
 |
 |
 |
|
Posted: 17/08/2010
Stopping anemia drug may be wiser than reducing dose to normalize hemoglobin levelsDiscontinuing anemia drug normalizes high hemoglobin levels in kidney disease patients.
Posted: 17/08/2010
The European Congress of Cardiology will be taking place at then end of the month (28 August -1st September 2010), in Stockholm, Sweden. Below are sessions that we think will be of particular interest to ITO members:
Read more >>
Posted: 02/07/2010
Since there are no data in the literature on the use of intravenous iron infusion in gastroenterology day hospitals, this study retrospectively reviewed the medical records of patients who received intravenous iron infusion in order to determine the indications, dosage and tolerance of intravenous iron infusion in outpatients attending a gastroenterology day hospital.
Read more >>
Posted: 01/07/2010
Patients with chronic kidney disease (CKD) are at elevated risk for cardiovascular disease events and the severity of anaemia has been associated with the magnitude of cardiovascular risk. Given the safety concerns raised in the treatment of anaemia with erythropoiesis-stimulating agents (ESAs) it has been suggested that an ESA dose-sparing approach to anaemia could mitigate this risk.
Read more >>
Posted: 01/07/2010
Breath-holding attacks are common during childhood and are distinct from seizures. Iron may reduce the frequency and severity of such attacks, but more research is needed to determine the extent of this effect.
Read more >>
Posted: 01/07/2010
In the clinical setting, serum ferritin evaluation is most commonly used to estimate body iron stores as low serum ferritin correlates with iron depletion, whereas high serum ferritin correlates with elevated body iron stores or with inflammation in patients with normal body iron stores. Characterization of serum ferritin has produced many controversial results regarding subunit composition, iron content and other features.
Read more >>
Posted: 01/07/2010
The peptide hepcidin is considered to play a central role in regulating iron status. Hepcidin binds to ferroportin, a cellular iron export channel protein, causing it to be internalized and degraded in lysosomes, which then prevents the efflux of iron from iron-exporting tissues into the plasma. It is suspected that an excess of hepcidin leads to dysregulation of iron metabolism in chronic kidney disease (CKD) patients, and such dysregulation has emerged as the key pathogenic feature in anemia of chronic disease (ACD).
Read more >>
Posted: 30/04/2010
Keeping up with the speed of medical discovery is one of the most formidable challenges physicians face. It is a responsibility that weighs more heavily upon the medical profession than any other professional group.
R.N. Bernstein, in the October 15, 2009 issue of Lang Speech Hear Serv Sch., offers some practical tips for keeping up with the medical literature, while at the same time balancing clinical uncertainty and doubt. He offers seven tips, one of which is to “understand that knowledge of "best practices" is both temporary and relative.” He then provides examples to “show that pro-active participation in research-alert programs can enable clinicians to access emerging, clinically-relevant information, some of which is controversial.”
Read more >>
Posted: 04/2010
A recent review of three retrospective studies of hemoglobin (Hb) variability in non-dialysis CKD (ND-CKD), revealed that the incidence of anemia in this population is at least 10-fold greater than that seen in the hemodialysis population, and that Hb variability is associated with a worse cardiorenal outcome.
Read more >>
Posted: 04/2010
Both the European School of Hematology (ESH) and the International Society of Hematology (ISH) are holding educational sessions this year with a particularly cutting edge focus on therapeutics in red blood cells and iron related disorders.
Read more >>
Posted: 29/03/2010
Findings from a recent comparative analysis of diagnostic tests for iron stores in patients with advanced chronic kidney disease (CKD), show equivalent but moderate usefulness for erythropoietic response and peripheral-iron indices, compared with bone marrow iron stores, and suggest that the use of these indices to determine iron depletion should be reconsidered.
Read more >>
Posted: 20/03/2010
The New England Journal of Medicine recently published the results of the FAIR-HF clinical trial conducted by Dr. Stefan Anker et al., on the effect of intravenous iron (ferric carboxymaltose) on the symptoms of patients who have heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. What is the anticipated clinical impact of this study? Dr. Anker answers this question in a recent interview.
Read more >>
Posted: 15/03/2010
The treatment of anemia in patients with Chronic Kidney Disease (CKD), who are not on dialysis, is absent in approximately 50% of the population seen within Veterans' Health Administration (VA). This compares with approximately 94% of the dialysis population who received erythropoiesis-stimulating agents (ESAs) at VA facilities, a new study reports.
Read more >>
Posted: 03/03/2010
According to the latest meta-analysis, erythropoiesis-stimulating agents (ESAs) showed no significant effect on survival, disease progression or safety outcomes in oncology patients. There was evidence, however, that ESA use did increase the risk for venous-thromoboembolic events, although without an increase in mortality.
Read more >>
Posted: 20/01/2010
The Network for Advancement of Transfusion Alternatives (NATA) is hosting its 11th Annual two-day conference on April 8 and 9, 2010. One of the many highlights will be a presentation and panel discussion on the results of the “FAIR-HF study on Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency.”
Read more >>
Posted: 10/12/2009
The European Hematology Association is hosting a scientific workshop in Cascais, Portugal, on April 15-18, 2010 to discuss the latest research and clinical significance of red cells and iron related therapies. The program features leading researchers from Europe, the Middle East and North America.
Read more >>
Posted: 27/11/2009
The stimulation of neutralizing antierythropoietin antibodies is a rare complication of recombinant human erythropoietin use in patients with the anemia of chronic renal failure. Macdougall, et al., report on the positive stimulatory effect that a novel, synthetic, peptide-based erythropoietin-receptor agonist had on erythropoiesis in patients with anemia caused by antierythropoietin antibodies.
Read more >>
Posted: 27/11/2009
The data from this pivotal study, lead Pfeffer, et al., to conclude that: “for many persons involved in clinical decision making, the [risk of stroke] will outweigh the potential benefits” of the use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who are not undergoing dialysis.
Read more >>
Posted: 27/11/2009
An intriguing phenomenon associated with anemia of inflammation is that approximately 70% of patients with inflammation have a mean corpuscular volume that is normal and a relatively mild degree of anemia. How is this explained?
Read more >>
Posted: 18/11/2009
The FAIR-HF study results indicate that intravenous (i.v.) iron (ferric carboxymaltose), significantly improves symptoms, exercise tolerance and quality of life in chronic heart failure patients. Ferric carboxymaltose was also well tolerated in this patient group and the safety and side effect profiles were well within acceptable ranges.
Read more >>
| Total number of results: 70 |
Page 1 of 4 |
First page | Previous | Next | Last page |
|
|
|
|
|
|
|
 |
